PEPD and Alzheimer disease: Importantly, in diseases that have been well characterized at the molecular–genetic and epigenetic level such as AD and PrD, miRNA-146a levels are found to progressively increase with disease severity and co-localize to brain anatomical compartments enriched in inflammatory neuropathology and end-stage amyloid and proteolipid deposition (29, 31, 32, 44).